6,940
Participants
Start Date
November 9, 2020
Primary Completion Date
October 30, 2024
Study Completion Date
October 30, 2024
VPM1002
"The active ingredient of the recombinant BCG vaccine, VPM1002 is Mycobacterium bovis A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Water for injection/vial"
BCG SII
"Commercially available BCG vaccine from Serum Institute of India Pvt. Ltd. A dose of 0.05 ml will be administered intradermally.~Manufactured by the Serum Institute of India Pvt. Ltd., India~Diluent: 1 ml of Sodium Chloride for injection/vial Injection"
Kenya Medical Research Institute - Center for Respiratory Disease Research, Siaya
Respiratory and Meningeal Pathogens Research Unit, Soweto
Empilweni Services and Research Unit (ESRU), Johannesburg
The national institute for Medical Research (NIMR) - Mbeya Medical Research Center (MMRC), Mbeya
South African Tuberculosis Vaccine Initiative, Worcester
Makerere University/CISMAC, Kampala
Family Center for Research with Ubuntu, Cape Town
Ifakara Health Institute, Dar es Salaam
Centre de Recherches Médicales de Lambaréné, Lambaréné
Medical Research Council / Uganda Virus Research Institute and London School of Hygiene and Tropical Medicines (MRC/UVRI and LSHTM) Uganda Research Unit, Entebbe
Kenya Medical Research Institute / Center for Respiratory Disease Research, Nairobi
Mecru Clinical Research Unit, Medunsa
Serum Life Science Europe GmbH
INDUSTRY
Serum Institute of India Pvt. Ltd.
INDUSTRY